The STRIDE protocol in hepatocellular carcinoma

Here, researchers present 4-year overall survival data from the HIMALAYA phase III clinical trial, evaluating the efficacy and safety of STRIDE (Single Tremelimumab Regular Interval Durvalumab) versus sorafenib in hepatocellular carcinoma. Patients were randomized to STRIDE, durvalumab or sorafenib. Overall survival at 36 months was 30.7% for STRIDE, versus 19.8% for sorafenib. Overall survival at 48 months remained better with STRIDE than with sorafenib. The long-term benefit of STRIDE was confirmed for all patient subgroups. At the same time, no new serious treatment-related adverse events were observed during this long-term follow-up.